And Valeant Pharmaceuticals teaming up for allergan. Well explain. Novartis unveiling a Restructuring Plan amid a flurry of deals involving glaxo and lily totalling 28. 5 billion. Netflix says it will raise prices for subscribers as the jump in earnings pushes the shares in premarket and slew of dow components reporting, mcdonalds, United Technologies, we have it covered. Shares of allergan are surging as we said bill ackman backing pharmaceutical bid to acquire the maker of botox, valeant offering 38. 40 a share in cash. Since february, Ackmans Pershing Square amassed a 9. 7 stake in allergan, but all the discussion guys, today, is about the role of the activist investorer. The times calls it the boldest move yet from an activist. Absolutely. I hope to hear from david. We were going back and forth last night about how does someone kind of basically know theres going to be a bid and be allowed to accumulate stock. Classically that would be front money. If we had an sec that was on the
This is a hearing about the pat, Patient Involvement in fda drug approvals, and i think we can agree they deserve a seat at the table. When companies are developing drugs and medical devices within the Clinical Trial process. I have long been a supporter of the department of defenses congressionallydirected medical Research Program known as the cdmrp. It funds peerreviewed research into Breast Cancer, autism, ovarian cancer, Prostate Cancer and other diseases. And since 1993 the patients have been involved and have been attar of cdmrp, and they have a consumer reviewer as part of the peerreviewed possible to represent the stakeholder community. And its been very successful in combining Patient Perspectives and needs with Scientific Research and bringing those perspectives together. Has fda, as you begin to consider improving Patient Involvement, have you looked at cdrmp to see if theres anything you can borrow from that in the drug approval process . Uhhuh. We have not, and thats a goo
Trials because they are being treated in places that are not running trials. We need to move this out in to the community, make those folks eligible. And im on the committee in the lung map trial, and i have really urged that we make sure that we are out there in the community so that anyone who has lung cancer has an opportunity to participate in the research and perhaps, have a more effective therapy. So, i think the Electronic Health records that its a huge different area that we are working on and how to do Clinical Trials utilizing the infrastructure that is emerging. Right, thank you very much. Chair, thanks, gentle lady, and now recognize gentleman from new jersey. Five minutes. Thank you very much, mr. Chairman. A focus of your testimony has been focused on fdas efforts on Patient Engagement. Its my understanding that clinicaltrials. Gov was intended to provide Clinical Study information for patients, Health Care Providers and researchers. But it seems to me that this site lack
And im on the committee in the lung map trial, and i have really urged that we make sure that we are out there in the community so that anyone who has lung cancer has an opportunity to participate in the research and perhaps, have a more effective therapy. So, i think the Electronic Health records that its a huge different area that we are working on and how to do Clinical Trials utilizing the infrastructure that is emerging. Right, thank you very much. Chair, thanks, gentle lady, and now recognize gentleman from new jersey. Five minutes. Thank you very much, mr. Chairman. A focus of your testimony has been focused on fdas efforts on Patient Engagement. Its my understanding that clinicaltrials. Gov was intended to provide Clinical Study information for patients, Health Care Providers and researchers. But it seems to me that this site lacks considerable information and has proven to be difficult to navigate. Dr. Woodcock, would you please comment on the current utility of clinicaltrials